Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Simcere Pharmaceutical Group (SCR) is Dedicated to Innovative Research and Development

Simcere Pharmaceutical Group is furthering its position in the rapidly growing China market. Headquartered in Nanjing, China, it is a manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals. As part of the Drug Manufacturing industry, it concentrates research and development on the treatment of diseases with high incidences and/or mortality rates. Shares trade on the New York Stock Exchange.

Simcere is focusing on drug medications for cancer, strokes, infectious diseases, and osteoporosis. They have introduced an anti-stroke medication under the brand name Bicun. They have also introduced an anti-cancer medication under the brand name Endu. The company makes and sells over 35 pharmaceutical products. These include antibiotics, and the anti-cancer and anti-stroke medications, as well as three other pharmaceuticals that they distribute exclusively under brand names.

Simcere Pharmaceuticals also has 12 product candidates at different levels of development. These include treatments for cancer, cerebrovascular diseases, infections, rheumatoid arthritis, and nasal allergies. They also include treatments for nausea and vomiting associated with chemotherapy.

Some of their other main branded generic offerings are amoxicillin capsules, dispersible tablets, granules, and injection under the brand Zailin. They also sell amoxicillin with clavulanate potassium granules, tablets, and injection under the name Anqi. In addition, they market smectite powder under the name Biqi. They also distribute prescription products made by third parties. These include generic diclofenac sodium sustained-release capsules under the brand Yingtaiqing. They also include generic alfacalcidol soft capsules under the name Faneng, and generic lentinan injection under the brand Yineng.

In May, Simcere Pharmaceutical Group obtained approval from Chinese regulators to market a generic Biapenem injection. The company obtained approval from the Chinese State Food and Drug Administration. The approval is to sell Anxin, a first-to-market generic version of Biapenem, used to treat serious infections.

Simcere Pharmaceutical Group markets and sells their products to regional pharmaceutical distributors. They then sell Simcere’s pharmaceuticals to local distributors, hospitals, and retail pharmacies. Founded in 1995, Simcere continues to innovate to improve quality of life for those suffering from serious diseases.

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *